Short answer
Aura Biosciences, Inc. (AURA) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$34M
- −22.6% YoY
- EPS (diluted)
- −$0.50
- +9.1% YoY
Source: XBRL data from the Aura Biosciences, Inc. (AURA) Q1 2026 10-Q on SEC EDGAR. USD.
Aura Biosciences, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material-change comparison provided; filing text begins mid-section and omits the 10-K baseline
- Liquidity risk: cash, equivalents, and marketable securities expected to fund operations into the second half of 2028
- Financial risk: net loss $33.7 million and accumulated deficit $514.1 million as of March 31, 2026
- Regulatory risk: bel-sar’s drug-device-laser combination creates greater approval uncertainty
- Operational risk: bel-sar remains the company’s only product candidate
- Capital-markets risk: no committed external funding source for development efforts
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aura Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.